Cerebral blood flow and end-tidal PCO2 during prolonged acetazolamide treatment in humans.
One oral dose of 1,000 mg of acetazolamide caused an acute 38% increase in cerebral blood flow (CBF) in eight healthy volunteers. During the following 10 days the subjects took 1,000 mg acetazolamide daily. CBF normalized within the first 2 days. The drug induced mild hyperventilation, gradually decreasing alveolar PCO2 to 70% of the control value at the end of the treatment period. In healthy humans the hyperventilation will not increase brain oxygenation significantly at sea level. But at high altitudes the enhanced ventilatory drive will improve oxygenation of the brain, and this may account for the beneficial effects of the drug on the symptoms of acute mountain sickness. During the treatment there was a significant 10% decrease of the hematocrit but an unaltered hemoglobin concentration. In combination with data in the literature our studies suggest that the initial CBF increase is a consequence of a transient extracellular acidosis dilating brain arterioles, whereas increased ventilatory drive results from a gradually increasing mild intracellular acidosis in the brain.
Friberg
L
L
Department of Clinical Physiology and Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark.
Kastrup
J
J
Rizzi
D
D
Jensen
J B
JB
Lassen
N A
NA
D000086:Acetazolamide / Q000009:adverse effects / Q000494:pharmacology*; D000328:Adult; D002245:Carbon Dioxide; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D005260:Female; D006400:Hematocrit; D006801:Humans; D008297:Male; D010292:Paresthesia / Q000139:chemically induced; D010313:Partial Pressure; D011650:Pulmonary Alveoli; D013990:Tidal Volume; D013997:Time Factors
D002245:Carbon Dioxide; D000086:Acetazolamide